Even as the diagnostics industry continues to pursue more sophisticated approaches to cancer testing, a group from the U.K. has come up with a simple blood test that could generate much more bang for the buck.
Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.
Mela Sciences has raised $27.3 million in new financing to help it win reimbursement and pursue more clinical testing for its MelaFind system, which has U.S. and EU approval to help dermatologists diagnose melanoma.
Quest Diagnostics saw its net income drop and earnings per share decline during the 2014 second quarter, as the company absorbed costs stemming from restructuring and M&A integration expenses. The New Jersey diagnostics giant has also adjusted full-year revenue projections for 2014.
Quest Diagnostics' partnership deal with a state-of-the-art French company is showing signs of paying off.
Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.
Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.
A three-year-old Pennsylvania startup pulled in the first tranche of a $11.6 million financing designed to help bring its first needle-based, minimally invasive diagnostic tool through regulatory clearance and commercial launch.
Norway's Bionor Pharma and U.K. scientists claim they've identified a biomarker in some patients that may be connected with an improved response to a therapeutic HIV vaccine now under development.
Revenue isn't yet growing fast enough for cancer diagnostics darling Foundation Medicine, making the recent New York State Department of Health approval of the Massachusetts company's two initial cancer tests all the more significant.
Abbott Laboratories reported solid sales gains in its core laboratory and point-of-care diagnostics lines during the 2014 second quarter, thanks to larger testing volumes and new products.
NeuroVision Imaging recently reported positive early results from a clinical trial using a digital eye-imaging diagnostic designed to help detect Alzheimer's related symptoms such as retinal plaque.
MGC Diagnostics continues its reinvention in 2014 with an eye on overseas growth. The Minnesota cardiorespiratory medical diagnostics outfit said it expects to complete the acquisition of a Belgian competitor by Aug. 1.
Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.
Asuragen gained approval to start offering two of its key molecular diagnostic tests in New York state, milestones that will help boost the standard of care and give the Texas company another opportunity to grow its market reach.
A biomarker previously linked with schizophrenia and found in saliva seems to say more nuanced things about the disease than previously thought, based on a new study that involved computer stress tests.
The Triangle Business Journal reported that the company will add a 25,500-square-foot addition to its existing facility, to produce products needed to help diagnose clinical sepsis.
A U.K. company aims to become the latest player in an already-packed prenatal diagnostics market, with plans to launch its first test in the European Union and Asia.
U.K. researchers from academia and industry say they've taken a big step forward in developing a viable Alzheimer's blood test. The advance is this: the discovery of 10 protein biomarkers in the blood that they assert can help predict the onset of the neurodegenerative disease.
In the wake of new venutre funding, FierceDiagnostics asked the CEO of tissue diagnostics comapny Definiens what will come next. The answer involves a range of bullish projections and enormous expectations.